市場調查報告書
商品編碼
1017196

全球單純皰疹病毒治療市場:2021∼2028年

Global Herpes Simplex Virus Treatment Market - 2021-2028

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球單純皰疹病毒治療的市場規模在預測期間(2021年∼2028年)預計將大幅成長。

單純皰疹病毒(HSV),即使皰疹感染疾病的原因也被知道。主要性器官和口中出現,不過,身體各種各樣的部位也能。是單純皰疹病毒有第一型(HSV-1)和2型(HSV-2)的2種,HSV-1到嘴唇和口周圍弄(引)起爛的口唇皰疹(熱水痘或寒症),HSV-2到性器官和直腸周圍弄(引)起爛的生殖器皰疹。

本報告提供全球單純皰疹病毒治療市場相關調查,提供市場概要,以及疫苗,各適應症,各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 全球單純皰疹病毒治療市場調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 全球單純皰疹病毒治療市場-市場定義和概要

第3章 全球單純皰疹病毒治療市場-摘要整理

  • 各疫苗的市場明細
  • 各適應症的市場明細
  • 各地區的市場明細

第4章 全球單純皰疹病毒治療市場-市場動態

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球單純皰疹病毒治療市場-產業分析

  • 波特的五力分析
  • PEST分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 全球單純皰疹病毒治療市場-COVID-19分析

  • 市場上的COVID-19分析
    • COVID-19前的市場方案
    • COVID-19目前市場方案
    • COVID-19後或未來方案
  • COVID-19的價格動態
  • 需求與供給的頻譜
  • 政府在COVID-19疫情下的市場相關措施
  • 製造商策略性舉措
  • 結論

第7章 全球單純皰疹病毒治療市場-各疫苗

    • 疫苗各市場區隔的市場規模分析,及與前一年同期比較成長分析(%)
    • 疫苗各市場區隔的市場魅力指數
  • GEN-003
    • 市場規模分析,一百萬美元,2018∼2028年,及與前一年同期比較成長分析(%)、2020∼2028年
  • VCL-HB01
  • HSV529
  • 其他

第8章 全球單純皰疹病毒治療市場-各適應症

    • 市場規模分析,及與前一年同期比較成長分析(%)、各適應症
    • 各適應症市場魅力指數
  • HSV-1(口唇皰疹)
    • 市場規模分析,一百萬美元,2018∼2028年,及與前一年同期比較成長分析(%)、2020∼2028年
  • HSV-2(生殖器皰疹)

第9章 全球單純皰疹病毒治療市場-各地區

    • 市場規模分析,一百萬美元,2018∼2028年,及與前一年同期比較成長分析(%)、2020∼2028年,各地區
    • 各地區的市場魅力指數
  • 北美
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%)、各疫苗
    • 市場規模分析,及與前一年同期比較成長分析(%)、各適應症
    • 市場規模分析,及與前一年同期比較成長分析(%)、各國
  • 歐洲
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%)、各疫苗
    • 市場規模分析,及與前一年同期比較成長分析(%)、各適應症
    • 市場規模分析,及與前一年同期比較成長分析(%)、各國
  • 南美
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%)、各疫苗
    • 市場規模分析,及與前一年同期比較成長分析(%)、各適應症
    • 市場規模分析,及與前一年同期比較成長分析(%)、各國
  • 亞太地區
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%)、各疫苗
    • 市場規模分析,及與前一年同期比較成長分析(%)、各適應症
    • 市場規模分析,及與前一年同期比較成長分析(%)、各國
  • 中東和非洲
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%)、各疫苗
    • 市場規模分析,及與前一年同期比較成長分析(%)、各適應症

第10章 全球單純皰疹病毒治療市場-競爭情形

  • 主要的發展與策略
  • 企業佔有率分析
  • 產品的基準
  • 值得注意的主要企業
  • 顛覆性技術的企業
  • Start-Ups企業

第11章 全球單純皰疹病毒治療市場-企業簡介概要

  • Sanofi S.A
    • 企業概要
    • 類型組合和概要
    • 主要的焦點
    • 財務概要
  • GlaxoSmithKline Plc
  • Genocea Biosciences, Inc
  • Vical, Inc
  • Novartis
  • Pfizer
  • Abbott Laboratories
  • Sun Pharmaceuticals
  • Valeant Pharmaceuticals
  • Teva Pharmaceutical

清單並未網羅全面

第12章 全球單純皰疹病毒治療市場-DataM

  • 附錄
  • 關於本公司·服務
  • 諮詢方式
目錄
Product Code: DMPH3504

Market Overview

The global herpes simplex virus Treatment Market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Herpes simplex virus (HSV) is also known for causing herpes infection. It is majorly found on genitals or the mouth and can also be seen on various body parts. There are two types of herpes simplex virus, type 1 (HSV-1) and type 2 (HSV-2), in which HSV-1 is oral herpes causing sores around lips and mouth (fever blisters or cold sores), while HSV-2 is genital herpes, wherein sores are found around genitals and rectum.

Market Dynamics

The herpes simplex virus treatment market growth is driven by the extensive research and development, growing prevalence of herpes simplex virus are the major factors responsible for the growth of this market.

The growing prevalence of herpes simplex virus, is expected to drive growth in the forecast period

According to the Centers for Disease Control and Prevention (CDC), in 2015, HSV-1 prevalence was 47.8%, while HSV-2 was 11.9% in the U.S. According to the same source, linear increase in prevalence for both HSV-1 and HSV-2 in people aged within 14-19 is 27%, for population aged within 20-29 is 41%, and for the age ranging within 30-39 and 40-49, it is 54.1% and 59.7%, respectively. According to the World Health Organization (WHO), in 2017, around 3.7 billion people (67%) under age 50 years suffered from HSV-1 infection, and 417 million (11%) people aged 15-49 years suffered from HSV-2 infection globally. This high prevalence rate has created the need for prevention and treatment of HSV, which is expected to support global herpes simplex virus (HSV) vaccines market growth.

Absence of prophylactic and therapeutic vaccine in the market is likely to hinder the market growth

Though many companies carry out clinical trials for HSV vaccines, there is an absence of prophylactic and therapeutic vaccine in the market. However, few trials have shown promising results for the prevention and treatment of HSV in clinical trials. Animal studies have shown possible results in clinical trials. However, different disease pathophysiology in animals and humans makes it difficult to produce the exact results in human trials. For example, clinical studies in mice and guinea pigs have produced more positive results than human trials, as human HSV infection is different from animal HSV infection. These factors have restricted the global herpes simplex virus (HSV) vaccine market growth.

COVID-19 Impact Analysis

Following the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries globally, and the World Health Organization has declared it a public health emergency. According to the World Health Organization's report, the coronavirus (COVID-19) manifestation has resulted in more than 52.7 million infected individuals worldwide as of November 13, 2020.

COVID-19 has affected every market globally and has also impacted the global herpes simplex virus treatment market in the following ways; by directly affecting production and demand, creating disruptions in distribution channels, and its financial impact on firms and financial markets.

Furthermore, players operating in the global herpes simplex virus treatment market face significant challenges on various fronts due to the COVID-19 pandemic. The significant challenges include the supply of raw materials for manufacturing drug formulations due to irregularities in the transportation facility. Moreover, distributors of products are experiencing irregular demand for products from the retailers due to the increasing patient population suffering from COVID-19 and other life-threatening disorders.

Segment Analysis

The GEN-003 segment is expected to hold largest share in this market segment

Genocea Biosciences, Inc. announced on May 19, 2020, entered into a material transfer agreement and exclusive license option with Shionogi & Co., Ltd. to develop a novel HSV-2 vaccine using Genocea's proprietary HSV-2 antigens from the GEN-003 program. GEN-003 is an experimental immunotherapy vaccine comprised of 2 HSV-2 proteins, glycoprotein D2. If license granted, Shionogi will assume responsibility for the global development and commercialization of the HSV-2 vaccine product. This will increase the demand for the Herpes Simplex Virus Treatment Market.

The HSV-1 (Oral Herpes) segment is expected to hold largest share in this market segment

According to the World Health Organization (WHO), regional infection prevalence estimates for HSV-1 among people range aged 0-49 years are 49% women and 39% men in the U.S., 87% women and 87% men in Africa, 69% women and 61% men in Europe, and 74% women and 73% men in western pacific are found, while for HSV-2 are found to be highest in Africa (31.5%) than compared to the U.S. (14.4%).

Geographical Analysis

North America region holds the largest market share of global herpes simplex virus treatment market

North America is expected to boost herpes simplex virus (HSV) vaccines market growth during the forecast period. Several leading companies are focusing on research and development of herpes simplex virus (HSV) vaccines to prevent it. For instance, GEN-003 of Genocea Biosciences, Inc. (based in the U.S.) has shown an acceptable safety profile in phase III clinical trials in 2017, so it could be the first upcoming vaccine available for HSV the market boosting global herpes simplex virus (HSV) vaccines market growth.

Competitive Landscape

The global herpes simplex virus treatment market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Sanofi S.A., GlaxoSmithKline Plc., Genocea Biosciences, Inc., Vical, Inc, Novartis, Pfizer, Abbott Laboratories, Sun Pharmaceuticals, Valeant Pharmaceuticals, Teva Pharmaceutical. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, Vical, Inc. has VCL-HB01 Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults with Symptomatic Genital HSV-2 Infection.

Herpes Simplex Virus Market Key Companies to Watch

Sanofi S.A

Overview: Sanofi S.A is a French multinational pharmaceutical company headquartered in Paris, France, as of 2013, the world's fifth-largest by prescription sales. Initially, the company was established in 1973 and merged with Synthelabo in 1999 to form Sanofi-Synthelabo. In 2004, Sanofi-Synthelabo merged with Aventis and renamed it to Sanofi-Aventis, each the product of several previous mergers. Finally, it changed its name back to Sanofi in May 2011 with 100000 employees, 69 manufacturing sites, 21 R&D sites.

Product Portfolio: The Company's portfolio comprised of Vaccines, Diabetes, Cardiovascular diseases, Neurology, Immunology, Oncology and rare diseases.

Key Developments: SP0148-Therapeutic vaccine is under Phase 1 study to treat Herpes simplex virus type 2 is developed in collaboration with Immune Design/Merck.

Why Purchase the Report?

  • Visualize the composition of the herpes simplex virus treatment market segmentation by vaccine, indication highlighting the key commercial assets and players.
  • Identify commercial opportunities in herpes simplex virus treatment market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of herpes simplex virus treatment market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global herpes simplex virus treatment market report would provide an access to an approx. 53 market data table, 42 figures and 200 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation:

Global Herpes Simplex Virus Treatment Market- By Vaccine

  • GEN-003
  • VCL-HB01
  • HSV529
  • Others

Global Herpes Simplex Virus Treatment Market- By Indication

  • HSV-1 (Oral Herpes)
  • HSV-2 (Genital Herpes)

Global Herpes Simplex Virus Treatment Market - By Region

  • North America
  • Europe
  • Asia-Pacific
  • Middle East & Africa
  • South America

Table of Contents

1. Global Herpes Simplex Virus Treatment Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Herpes Simplex Virus Treatment Market - Market Definition and Overview

3. Global Herpes Simplex Virus Treatment Market - Executive Summary

  • 3.1. Market Snippet by Vaccine
  • 3.2. Market Snippet by Indication
  • 3.3. Market Snippet by Region

4. Global Herpes Simplex Virus Treatment Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Driver
      • 4.1.1.1. The growing prevalence of herpes simplex virus
    • 4.1.2. Restraints:
      • 4.1.2.1. Absence of prophylactic and therapeutic vaccine
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Herpes Simplex Virus Treatment Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. PEST Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. Global Herpes Simplex Virus Treatment Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Herpes Simplex Virus Treatment Market - By Vaccine

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Segment
    • 7.1.2. Market Attractiveness Index, By Vaccine Segment
  • 7.2. GEN-003*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3 VCL-HB01
  • 7.4 HSV529
  • 7.5 Others

8. Global Herpes Simplex Virus Treatment Market - By Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 8.1.2. Market Attractiveness Index, By Indication
  • 8.2. HSV-1 (Oral Herpes) *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. HSV-2 (Genital Herpes)

9. Global Herpes Simplex Virus Treatment Market - By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

10. Global Herpes Simplex Virus Treatment Market - Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Benchmarking
  • 10.4. Key Companies to Watch
  • 10.5. Company with disruptive technology
  • 10.6. Start Up Companies

11. Global Herpes Simplex Virus Treatment Market- Company Profiles

  • 11.1. Sanofi S.A*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. GlaxoSmithKline Plc
  • 11.3. Genocea Biosciences, Inc
  • 11.4. Vical, Inc
  • 11.5. Novartis
  • 11.6. Pfizer
  • 11.7. Abbott Laboratories
  • 11.8. Sun Pharmaceuticals
  • 11.9. Valeant Pharmaceuticals
  • 11.10. Teva Pharmaceutical

LIST NOT EXHAUSTIVE

12. Global Herpes Simplex Virus Treatment Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us